Objective: Somatotropinomae are classified as densely and sparsely granulated adenomae, which typically exhibit a perinuclear pattern (PP) and a dot pattern (DP) in cytokeratin (CK) immunostaining respectively. Some exhibit a mixed pattern (MP). We studied the relationship between these somatotropinoma subtypes and their clinico-pathological features. Methods: The study population consisted of 141 Japanese acromegalic patients. We evaluated their clinical presentation and their response to provocation tests with TRH and LHRH and to suppression (octreotide) test. Tumour tissues were subjected to immunostaining for CAM-5.2, MIB-1, CD34, E-cadherin (CDH1) and p53 (TP53). In 43 cases (30 non-DP and 13 DP), we analysed gsp mutations (constitutively activating mutations of the G s a protein that is encoded by GNAS gene). Results: The 141 adenomae were categorised into three subtypes based on their CK staining patterns; 30 (21.3%) exhibited DP, 83 (58.9%) exhibited PP, and 28 (19.9%) exhibited MP. Compared with the other subtypes, DP adenomae were significantly larger, and their E-cadherin expression and response to TRH, LHRH and octreotide challenge were lower. The postoperative cure rate tended to be lower in DP adenomae. gsp mutations were detected in 25 of 43 cases examined (58.1%); 20 of the 30 non-DP (66.7%) and 5 of the 13 DP tumours (38.5%) were affected by the mutation. Conclusion: DP somatotropinomae exhibit characteristic features. Compared with the non-DP subtypes, DP adenomae manifested a larger tumour size, a lower incidence of abnormal responses to TRH and LHRH challenge, a poor response to octreotide test and a lower expression of E-cadherin. gsp mutation was not exclusive for non-DP somatotropinomae.
Introduction
Human pituitary adenomae are benign neoplasms that account for about 15-20% of all intracranial neoplasms (1) (2) (3) . Based on their electron microscopic features, somatotropinomae or GH-producing adenomae (GHomae) that produce acromegaly and gigantism are classified into two subtypes (1, 4, 5) , i.e. densely and sparsely granulated (DG and SG) tumours. The DG subtype manifests abundant closely packed secretory granules of large to medium size. Most tumour cells are polyhedral or elongated with spherical euchromatic nuclei containing conspicuous nucleoli. In the cytoplasm, well-developed Golgi apparatus harbouring immature developing granules and elongated cristae in the mitochondria are observed (1, 4, 5) . These features are distinct from SG subtype adenoma cells whose cytoplasm contains scarcely distributed small secretory granules and fibrous bodies. The perinuclear pattern (PP) and dot pattern (DP) in cytokeratin (CK) immunostaining observed under light microscopy can be good surrogate for the electron microscopic features of the DG and SG subtype adenomae respectively (1, 6) . However, there are some adenomae that exhibit a combined feature of PP and DP or the mixed pattern (MP) (7) (8) (9) (10) (11) .
The fibrous body is an intracytoplasmic globular aggregation of filaments containing CK, which belongs to the intermediate filament protein family (6, 7, (12) (13) (14) . Apart from its role in the formation of cell frameworks, CK has other important functions, and disorganised CK distribution may result in the disruption of cellular functions (14) . The CK immunostaining pattern is related to epithelial malignancies and reflects ongoing cell activity (15) . However, the molecular background and pathophysiology of the two GHoma phenotypes remain to be elucidated.
The gsp mutation is a somatic activating mutation of the a subunit of the heterotrimeric G s protein encoded by the GNAS gene (16, 17) . It is thought to be an early event in tumourigenesis and is detected in w40-50% of sporadic GHomae (18) (19) (20) (21) (22) . There have been few studies on the impact of gsp mutations on the GHoma subtypes (19, 23) ; this mutation has been documented only in DG GHomae (19, 23) .
In this study, we retrospectively evaluated clinicopathological features of GHomae with their respective CK pattern in acromegalic patients. The relationships between the CK pattern and gsp mutation were investigated as well.
Materials and methods

Subjects
The study population consisted of 141 Japanese patients with GHoma who underwent transsphenoidal adenomectomy in our hospitals. Before surgery, none had been treated with dopamine receptor subtype-2 (D 2 ) agonists, somatostatin analogues (except for the single challenge test) or irradiation.
Acquisition of clinical data
Clinical data and the patient's age and sex, symptoms, hormonal profiles and tumour morphologies were obtained from clinical records and preoperative magnetic resonance imaging (MRI) scans.
Hormonal evaluation
Plasma GH and insulin-like growth factor 1 (IGF1) levels were measured for routine preoperative endocrine evaluation. The GH responses to TRH (500 mg, i.v.), LHRH (100 mg, i.v.) and octreotide (50 mg, s.c.), expressed as the ratio (%) of the maximum or minimum GH level to the basal GH level, were evaluated on different days. An abnormal response to TRH or LHRH was defined as an increase in the GH level to 200% or more of the baseline value. A good response to the octreotide test was defined as a R90% or greater decrease in the GH level from the baseline during testing. Postoperative cure was defined according to the Cortina consensus criteria (24), i.e. as a GH nadir during postoperative oral glucose tolerance test (OGTT, !1 ng/ml) and normalisation of serum IGF1 based on the standard value for the Japanese population. Of the 141 patients, 127 underwent postoperative OGTT.
Imaging studies
The maximum tumour diameter was measured on preoperative MRI scans. The tumour volume (cm 3 ) was estimated using the formula: 0.5!width!length! height (25) . Cavernous sinus invasion by the tumour was judged to be present when the preoperative MRI scan showed an internal carotid artery surrounded by the tumour (Knosp's grade IV lateral growth) (26) or when there was intraoperative microscopic and/or endoscopic evidence of disruption of the medial wall of the cavernous sinus and lateral extension of the tumour through the window.
Patients with a documented history of pituitary apoplexy were excluded from this study. GH-producing indices were calculated based on the ratio of the preoperative GH level (ng/ml) per cm 3 of the tumour volume (ng/ml per cm 3 ) (8).
Histological studies
Surgically isolated adenomae tissues were fixed in 10% formaldehyde and embedded in paraffin before cutting into thin slices (3 mm thick) for light microscopy and light microscopic immunohistochemistry. DP and PP). Cells immunoreactive to GH, prolactin (PRL), TSH and p53 were counted and expressed as a percentage of stained cells of more than 500 adenomae cells at 400! magnification. Cells immunoreactive to E-cadherin (CDH1) were also quantitatively assessed and expressed as a percentage of cells that stained positive on the plasma membrane. The microvascular density (MVD) was assessed by counting the number of lumen with CD34 positive staining at 400! magnification. MIB-1 index reflecting proliferating cell ratio was calculated from more than 500 cells.
gsp gene mutation study
For gsp mutation analysis, 43 frozen GHoma specimens were available. Their number was restricted because in some cases the amount of tumour tissue was too small to be prepared as frozen sample or because protocols for the acquisition of frozen tissues were not uniform. Two authors (K T and J Y-T), blinded to clinical and pathological data, subjected the available frozen tissues to mutation analysis. The mean diameter of the 43 tumours used for mutation analysis and of all 141 tumours was similar (19.6G8.1 mm (S.D.) and 18.7G9.6 mm respectively). The specimens were preserved under K80 8C until RNA extraction. Total RNA contents were extracted from the adenomae tissues, and the first-strand cDNA was synthesised from 5 mg total RNA by RT-PCR after removing contaminating genomic DNA as reported previously (18) . To amplify the specific G s a-subunit cDNA fragment (249 bp), including codons 201 and 227 of the Gsa gene, we designed a sense primer and an antisense primer corresponding to nucleotide sequences 562-585 (5 0 -GTGTATCAAGCAGGCTGACTATGTG-3 0 ) and 793-819 (5 0 -CAGGCGGTTGTTCTGGTT-3 0 ) respectively. Using these primers, the PCR was performed to amplify the aforesaid first-strand cDNA, although the temperature for annealing was changed to 60 8C for 40 cycles. The PCR product was purified and directly sequenced using ABI PRISM software (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
The SPSS software program (version 15.0, IBM Co., Chicago, IL, USA) was used for statistical analysis of the results. The data was analysed by the contingency C test followed by Fisher's exact test, the Kruskal-Wallis test and/or the Mann-Whitney U test where appropriate. Differences of P!0.05 were considered statistically significant.
Ethical considerations
This retrospective study was approved by the Kagoshima University Hospital Ethical Committee (reference no: 2008-144).
Results
As we found that the clinical features of MP and PP adenomae were similar, we present our findings as comparisons between DP and non-DP (i.e. combined MP and PP) GHomae.
Patient profiles
The gender distribution in the 141 patients, 64 males and 77 females, was comparable; their age ranged from 9 to 75 years (48.9G13.5, meanGS.D.; Table 2 ). The mean preoperative GH level was 62.1G183.7 ng/ml. Abnormal responses to TRH and LHRH tests were observed in 75 and 16.7% of 128 patients respectively; 12 (30.8%) of 39 patients had a good response to the 
CK patterns and clinical features
Based on the classification criteria described in Materials and methods, of the 141 tumours, 30 (21.3%) were DP ( Fig. 1A and B) , 83 (58.9%) were PP ( Fig. 2A and B) , and 28 (19.9%) were MP subtype tumours ( Table 3 ). The mean age tended to be lower in patients with DP adenomae than those with non-DP adenomae (45.0G16.1 vs 50.1G12.6 years, PZ0.098). The mean maximal tumour diameter of DP, PP and MP adenomae was 23.5G11.5, 17.5G8.9 and 16.8G8.2 mm respectively; DP GHomae were significantly larger than non-DP tumours (PZ0.006). The volume of DP GHomae was also significantly larger than that of non-DP adenomae (11.7G18.4 vs 5.3G10.9 cm 3 , PZ0.006). GH-producing index tended to be lower in DP adenomae (17.3G22.2 ng/ml per cm 3 ) than in non-DP adenomae (23.2G39.1 ng/ml per cm 3 ) (PZ0.145). On the other hand, with respect to tumour invasiveness, there was no significant difference between the tumour types.
Significantly more patients with non-DP tumours than those with DP tumours manifested an abnormal response to TRH (81.2 vs 51.9%, PZ0.003) and LHRH challenge (19.8 vs 3.7%, PZ0.034) and a good response to octreotide (42.9 vs 0%, PZ0.008).
Of the 127 patients who underwent postoperative OGTT, 72 (56.7%) obtained postoperative cure. Although the postoperative cure rate was better in patients with non-DP adenomae than those with DP adenomae (60.4 vs 42.3%), the difference was not statistically significant (PZ0.076).
Immunohistochemistry
Most of the adenoma cells were diffusely immunoreactive with GH (Figs 1C and 2C ; Table 4 ). Between DP and non-DP adenomae, there was no significant difference in the percentage of GH-immunopositive cells, nor in the percentage of cells immunopositive for other anterior pituitary hormones. The MIB-1 index was higher in DP GHomae than in non-DP GHomae (0.72G1.6 vs 0.20G0.39%, PZ0.086). The expression of MVD was almost the same between the two groups. Although not statistically significant (PZ0.101), the expression of p53 was slightly higher in DP GHomae. Lastly, the expression of E-cadherin involving the CK network (27-29) was significantly (P!0.001) lower in DP GHomae than in non-DP GHomae (Figs 1D and 2D ).
gsp mutations
The mutation was detected in 25 of 43 (58.1%) tumours examined. Incidence of gsp mutation tended to be higher in non-DP (66.7%) adenomae than in DP (38.5%) adenomae (PZ0.083; Table 5 ). There were four different mutations; they were Arg to Cys in codon 201 (68%), Arg to Ser in codon 201 (8%), Gln to Leu in codon 227 (20%) and Gln to Arg in codon 227 (4%).
The clinico-pathological features (including age, sex, basal GH level and MIB-1 index) of the 43 patients whose tumours were subjected to mutation analysis were not significantly different, irrespective of their mutation status. Also, there was no significant difference with respect to immunoreactivity to GH, PRL or TSH (data not shown). On the other hand, the tumour size was significantly smaller (PZ0.006) and the GH-producing index was significantly larger (PZ0.007) in adenomae with gsp mutations than those without gsp mutations. In addition, while all tumours with the mutation manifested an abnormal response to TRH challenge, this was the case in 50% of adenomae without gsp mutations (P!0.001). We observed a good response to octreotide in 44.4% of adenomae with gsp mutations and in 18.2% of tumours without the mutation; the difference was not significant (PZ0.217), possibly because our sample size of cases who underwent octreotide test (nZ20) was too small for statistical evaluation. Abnormal response, increases of the GH level to 200% or more; a good response, R90% decreases in GH levels from the preoperative basal GH level during examination; cured, nadir GH during glucose tolerance test !1.0 ng/ml and normalised IGF1 level (based on standard value for normal Japanese population).
Discussion
The classification of GHomae based on their CK immunostaining patterns results in three subtypes, i.e. DP, PP and MP tumours (7-11). We found some different clinico-pathological features in DP adenomae than in non-DP adenomae.
CK staining patterns and clinico-pathological features
The age tended to be lower in patients with DP than those with non-DP GHomae (PZ0.98). This finding coincides with the report of Mazal et al. (11) and Obari et al. (9) . With respect to the tumour size, our findings were similar to the findings reported by Mazal et al. (11) who also observed that DP adenomae were significantly larger than non-DP adenomae. While the difference was not statistically significant (PZ0.086), the MIB-1 index, indicative of the proliferative activity of tumour cells, tended to be higher in our patients with DP adenomae than those with non-DP adenomae. According to Mazal et al. (11) , it was significantly higher in DP tumours than in PP tumours, suggesting that the DP subtype may be more highly proliferative. One of our patients manifested an atypical GHoma that regrew rapidly and recurred postoperatively; the MIB-1 index was w10%, and 23% of the cell nuclei were positive for p53. Based on CK immunostaining, this tumour was classified as a DP subtype adenoma. In our study, more DP tumours than non-DP tumours expressed p53, although the difference was not statistically significant (PZ0.101). Our patients with DP adenomae were younger than those with non-DP tumours, possibly because the former subtype is more highly proliferative and consequently, these tumours tend to be larger. Besides excessive GH secretion, cranial nerve signs and headache may be clues for a diagnosis of acromegaly, and these non-hormonal manifestations may appear earlier in patients with DP adenomae due to their larger size. The expression of E-cadherin was significantly lower in DP adenomae than in non-DP adenomae (P!0.001); a finding that coincides with observations reported by others (8, 10) . The E-cadherin cell adhesion system is involved in cell-cell interactions via coupling to cytoskeleton-associated desmosomal proteins (27) . As E-cadherin is critical for the anchoring of CK filaments to the cell surface, the loss of E-cadherin expression on e No microadenomae showed evident cavernous sinus invasion confirmed by intraoperative exposure. f Cured: nadir GH during glucose tolerance test !1.0 ng/ml and normalised IGF1 level (based on standard value for normal Japanese population).
the cell membrane results in CK collapse (28) and may facilitate the formation of a fibrous body that stains with CAM-5.2 in GHomae. As the disruption of cell-cell contact is a key step in tumour progression, the loss of E-cadherin expression has been observed in various carcinomas (29) . The disruption of cell-cell contact due to impaired E-cadherin expression may be a factor in the growth of DP adenomae. Other factors influencing tumour growth, such as apoptotic process, cell-cell junction and intercellular communication, should be further investigated to understand the linking mechanisms between CK expression and tumour growth. DP adenomae did not have the tendency to be more invasive than the other types; a finding that is inconsistent with the reports by Mazal et al. (11) and Obari et al. (9) , where both groups determined invasion by Knosp grading (26) . However, we evaluated the invasion into cavernous sinus based on intraoperative findings under microscopic and/or endoscopic observations in addition to preoperative MRI findings. The discrepancy may have resulted from the difference in defining 'invasion'.
With respect to hormone production, we found no significant difference in immunoreactivity to GH, TSH and PRL between DP and non-DP adenomae. Although statistically insignificant, the GH-producing index was lower in DP adenomae than in non-DP adenomae in our study. This could have been due to the larger tumour size and smaller number and size of secretion granules (electron microscopic features) of DP adenomae than those of PP adenomae (1). Accordingly, Nishioka et al. (8) have also reported that an increased percentage of fibrous body is associated with lower basal GH levels per unit volume of tumour tissue and decreased immunoreactivities to GH and PRL. We routinely perform TRH and LHRH tests on patients with GHoma to assess the preoperative and postoperative secretory dynamics of the pituitary hormones: TSH, PRL, LH and FSH. Abnormal GH responses to these tests provide additional evidence for acromegaly, and persistent abnormal responses to TRH challenge in cured acromegalics are thought to be predictive of recurrence (30) . In this study, the incidence of abnormal response to preoperative TRH or LHRH challenge test was significantly (P!0.05) lower in DP adenomae than in non-DP adenomae. Ectopic TRH receptors in GHomae cells play an important role in the abnormal GH response to TRH (31) . Physiologically, TRH receptors act via the inositol 1,4,5-triphosphate pathway to release TSH and PRL (32, 33) . However, ectopically expressed TRH receptors cross-couple with cAMP and regulate GH secretion by somatotroph cells (34) , and the abnormal GH response is more frequently observed in adenomae with gsp mutation than those without the mutation (35) as is in our series. As gsp mutation was more frequently encountered in non-DP adenomae in this study, it is thus rational to expect TRH receptor prevailed more frequently in DG GHomae than in SG ones (31) . Ectopic expression of TRH receptors may couple with tumourigenesis of GHomae (triggered by gsp mutation) and amplified cAMP signalling (36, 37) .
The response rate to the prolonged administration of octreotide was reported to be significantly higher in patients with DG adenomae than those with SG adenomae (38, 39) . In our series, the response to octreotide was higher in patients with non-DP adenomae than those with DP adenomae. In fact, all patients manifesting a good octreotide response had abnormal responses to TRH challenge, while this was true for 55.6% of patients with a poor response to octreotide (data not shown in table). The difference in the frequency of positive response to octreotide test may be partially due to the different gsp mutation prevalence between DP and non-DP adenomae. Somatostatin receptor subtype-2 (SSTR2), to which octreotide preferentially binds, is overexpressed by the constitutive activation of adenylyl cyclase in GHomae with gsp mutation (40). Nakashima et al. (41) have reported that adenomae with gsp mutation are more likely to display plasma membrane-dominant staining of SSTR2A. Elucidating the differences in expression and distribution of somatostatin receptors and their intracellular signalling between DP and non-DP GHomae cells are themes that need further investigation.
Postoperative cure rate was better in non-DP adenomae (60.4%) than in DP adenomae (42.3%) in our series (PZ0.076), which would be a reflection of the smaller volume in non-DP adenomae. Lack of the statistical significance may be due to relatively lower GH productivity of DP adenomae. Because of the lower GH productivity, patients with limited residual adenomae tissue with DP might be judged as 'cured' by the current consensus criteria of cure (42) .
gsp mutations and CK staining pattern
Although the number of adenomae available for analysis of the relationship between gsp mutations and the CK staining pattern was limited (nZ43), we found that 38.5% of the DP tumours manifested the mutation. This finding differs from the observations reported by Asa et al. (23) , suggesting that in GHomae the CK architecture may not be related directly with gsp-induced tumourigenesis.
The rate of the gsp mutation in our series (58.1%) is comparable to the rate reported in Caucasian patients (19) (20) (21) and in a recent series of 100 Japanese patients (53.0%) (18) . In studies reported in 1993, the incidence of gsp mutations in Japanese acromegalics was low as 9.3 and 4.4% (43, 44) ; however, re-evaluation performed 10 years later by the same authors indicated that the corrected incidence was 53.1% (45) .
Findings on the relationship between the presence of gsp mutations and tumour size have been discordant (19) (20) (21) 46 ). In our study, adenomae with gsp mutations were significantly smaller (P!0.01) than tumours without gsp mutations. We posit that the smaller size of our non-DP adenomae may be partly attributable to the higher incidence of gsp mutations in that adenoma subtype.
Conclusion
DP somatotropinomae exhibit characteristic features. Compared with the non-DP subtypes, the DP tumours were larger; patients with DP tumours had a lower incidence of abnormal responses to TRH and LHRH challenge and a poorer response to octreotide test. Lastly, the E-cadherin expression level was lower in DP adenomae than in non-DP adenomae, a factor that may explain their larger size. Both DP and non-DP tumours manifested gsp mutations. Additional investigations are necessary to elucidate the molecular background of the observed differences in the CK staining patterns and to understand their relationship with tumourigenesis.
